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TransportThe role of hydrophobic residues of the mitochondrial carnitine/acylcarnitine carrier (CAC) in the inhibition
by acylcarnitines has been investigated by site-directed mutagenesis. According to the homology model of
CAC in cytosolic opened conformation (c-state), L14, G17, G21, V25, P78, V82, M85, C89, F93, A276, A279,
C283, F287 are located in the 1st (H1), 2nd (H2) and 6th (H6) transmembrane α-helices and exposed in
the central cavity, forming a hydrophobic half shell. These residues have been substituted with A (or G)
and in some cases with M. Mutants have been assayed for transport activity measured as [3H]carnitine/car-
nitine antiport in proteoliposomes. With the exception of G17A and G21M, mutants exhibited activity from
20% to 100% of WT. Among the active mutants only G21A, V25M, P78A and P78M showed Vmax lower
than half and/or Km more than two fold respect to WT. Acylcarnitines competitively inhibited carnitine anti-
port. The extent of inhibition of the mutants by acylcarnitines with acyl chain length of 2, 4, 8, 12, 14 and 16
has been compared with the WT. V25A, P78A, P78M and A279G showed reduced extent of inhibition by all
the acylcarnitines; V25M showed reduced inhibition by shorter acylcarnitines; V82A, V82M, M85A, C89A
and A276G showed reduced inhibition by longer acylcarnitines, respect to WT. C283A showed increased ex-
tent of inhibition by acylcarnitines. Variations of Ki of mutants for acylcarnitines reﬂected variations of the
inhibition proﬁles. The data demonstrated that V25, P78, V82, M85 and C89 are involved in the acyl chain
binding to the CAC in c-state.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The mitochondrial carnitine/acylcarnitine carrier (CAC) plays an
essential role in the ß-oxidation of fatty acids [1]. After the initial
studies in intact mitochondria, the function of the CAC has been
extensively investigated by reconstituting the puriﬁed protein in lipo-
somes [2–4]. In proteoliposomes the CAC catalyses efﬁcient carnitine/aleimide; Pipes, 1,4-piperazi-
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ports and, in the absence of counter-substrate, a 10 times slower car-
nitine uniport. The transporter is functionally asymmetrical and is
inserted in the proteoliposomal membrane in a right-side out orien-
tation as compared to mitochondria. The functional asymmetry of
the transporter correlates well with its physiological role. Indeed,
the CAC shows, on the external cytosolic side, higher afﬁnity towards
acylcarnitines than for free carnitine; furthermore the afﬁnity for
acylcarnitines is higher respect to the matrix side. These kinetic prop-
erties cause preference for transport of acylcarnitines, respect to car-
nitine, into the mitochondrial matrix, where the acyl groups are
transferred to CoA and subjected to β-oxidation. The free carnitine
released in the matrix is translocated by the antiport reaction towards
the cytosol [1,4]. The amino acid sequence of the CAC possesses all the
features of the mitochondrial carrier protein family [5], i.e., three re-
peated segments of about 100 amino acids, each containing the signa-
ture motif PX[DE]XX[RK]. As in the case of the other members of the
family, in the CAC sequence six hydrophobic transmembrane seg-
ments (H1–H6) can be identiﬁed by hydropathy analysis. These
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exposed towards the cytosolic side (h23, h45) and three towards the
matrix side (h12, h34, h56) of the protein; the three matrix loops are
much larger than the cytosolic ones. The CAC is present in several
species. Among the various unicellular or multicellular organisms in
which it has been identiﬁed by biochemical or genomic approaches
the CAC is encoded in Homo sapiens by the gene SLC25A20 [6] that
maps to chromosome 3p21.31 [7], in Saccharomyces cerevisiae by
the gene CRC [8] and in Aspergillus nidulans by the gene acuH [9].
The rat and the human CAC have been over-expressed in Escherichia-
coli and the recombinant proteins have been reconstituted in lipo-
somes. The reconstituted proteins show functional and kinetic
properties very similar to those of the native rat transporter [10,11].
Combining site-directed mutagenesis, chemical targeting and bioin-
formatics, the CAC has been characterized from the structural point
of view. The homology structural model of the CAC was built using
the ANC structure as template [12]. This model has been validated
by experimental evidence demonstrating that C136 is located in the
water-ﬁlled cavity. Furthermore, it was found that C136 and C155,
which are distantly located in the primary structure, can become
closer during some steps of the transport cycle demonstrating the
occurrence of conformational changes of the protein induced by the
interaction of the substrate with the transporter and involving both
hydrophilic and hydrophobic residues [12,13]. In analogy with the
ANC, in the structural model of the CAC, six conserved charged resi-
dues of the three conserved motifs constitute a salt bridge network,
closing the central cavity of the transporter towards the matrix side.
This structural feature has been conﬁrmed by site-directed mutagen-
esis studies, which, moreover, demonstrated that K35 and E132,
which are involved in the salt-bridge network, play a major role in
opening and closing the matrix gate. The amino acid residues R275,
D179 and R178 of CAC have been found to be involved in the binding
of the zwitterionic substrate carnitine [14], while the residue H29
plays a role in positioning of the substrate during the translocation
[15]. However, the physiological substrates that enter the mitochon-
drial matrix are acylcarnitines [1,16]. These substrates have large hy-
drophobic moieties, which should bind hydrophobic amino acid
residues. Using site-directed mutagenesis together with molecular
modeling and docking, the residues that are implied in the binding
of acyl moieties of acylcarnitines have been identiﬁed.
2. Experimental procedures
2.1. Materials
Sephadexes G-50, G-75 and G-200were purchased from Pharmacia,
L-[methyl-3H]carnitine from Amersham, egg-yolk phospholipids (L-α-
phosphatidylcholine from fresh turkey egg yolk), Pipes, Triton X-100,
cardiolipin, L-carnitine, acylcarnitines (acetyl-DL-carnitine, butyryl-L-
carnitine, octanoyl-DL-carnitine, lauroyl-DL-carnitine, myristoyl-DL-
carnitine, palmitoyl-L-carnitine and N-dodecanoylsarcosine (sarkosyl)
from Sigma-Aldrich. All other reagents were of analytical grade.
2.2. Site-directed mutagenesis, overexpression and isolation of the CAC
proteins
The previously constructed pMW7-WTratCAC recombinant plas-
mid was used to introduce the mutations in the CAC protein [17].
The amino acid replacements were performed with complementary
mutagenic primers using the overlap extension method [18] and the
High-Fidelity PCR System (Roche). The PCR products were puriﬁed
by the QIAEX II Gel Extraction Kit (QIAGEN), digested with NdeI and
HindIII (restriction sites added at the 5' end of forward and reverse
primers, respectively) and ligated into the pMW7 expression vector.
All mutations were veriﬁed by DNA sequencing, and except for the
desired base changes, all the sequences were identical to that of ratCAC cDNA. The resulting plasmids were transformed into E. coli
C0214. Bacterial overexpression, isolation of the inclusion body frac-
tion, solubilization and puriﬁcation of the WT CAC and mutant CAC
proteins were performed as described previously [10,17].
2.3. Reconstitution of WT and mutant CAC proteins in liposomes
The recombinant proteins were reconstituted into liposomes as
described previously [10,17]. The concentration of intraliposomal
carnitine was 15 mM. The external substrate was removed from
proteoliposomes on Sephadex G-75 columns.
2.4. Transport measurements
Transport at 25 °C was started by adding 0.1 mM [3H]carnitine to
proteoliposomes and terminated by the addition of 1.5 mM NEM. In
controls, the inhibitor was added together with the labeled substrate,
according to the inhibitor stop method [19]. This strategy allows to
subtract from the experimental samples the aliquot of radiolabeled
carnitine diffusing through the liposomal membrane. Finally, the ex-
ternal substrate was removed by chromatography on Sephadex G-
50 columns, and the radioactivity in the liposomes was measured
[19]. The experimental values were corrected by subtracting control
values. All of the transport activities were determined by taking into
account the efﬁciency of reconstitution (i.e., the share of successfully
incorporated protein).
2.5. Other methods
SDS-PAGE was performed according to Laemmli [20] as previously
described [10]. The amount of recombinant protein was estimated
on Coomassie blue-stained SDS-PAGE gels by the Bio-Rad GS-700
Imaging Densitometer equipped with the software Bio-Rad Multi-
Analyst, using bovine serum albumin as standard. The extent of incor-
poration of the recombinant protein in liposomes was determined
as described in Phelps et al. [21], with the modiﬁcations reported in
ref. [17]. The homology model of the human CAC was built based
upon the structure of the bovine ADP/ATP carrier [22] by using the
computer application Swiss PDB Viewer [23]. The hydrophobicity of
α-helices has been calculated as GRAVY (grand average of hydro-
pathicity) [24] using the bioinformatic tool ProParamTool (http://
www.expasy.ch/tools/protparam.html). Prediction of the position of
the substrate palmitoylcarnitine in the protein binding site has been
performed using the software ArgusLab [25].
3. Results
3.1. Bioinformatic analysis
To predict which of the hydrophobic amino acid residues of CAC
could be involved in the interaction with the acyl moieties of acylcar-
nitines, a bioinformatic analysis has been performed. The grand aver-
age of hydropathicity (GRAVY) [24] has been calculated for each
α-helix of the CAC. α-Helices H1 (GRAVY, 0.80), H2 (0.84), H5
(0.84) and H6 (0.91) are more hydrophobic than H3 (0.40) and H4
(−0.16). Accordingly, the top view of the protein showing the
residues protruding in the central cavity, highlights that most of the
hydrophobic residues are grouped in an half shell, constituted by
H1, H2 and H6 (Fig. 1). The hydrophobic half shell might contain
the binding sites for acyl groups of acylcarnitines. This hypothesis
has been evaluated using site-directed mutagenesis. Differently
from CAC, hydrophobic residues protruding towards the cavity in
transporters for charged substrates, such as the PIC, CIC and ANT are
uniformly distributed among the six α-helices (not shown).
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Fig. 1. Top view of CAC structural model. Surface representation in which the superﬁ-
cial residues protruding towards the central cavity are visible. The arrows, pointing to
the cytosolic end of each transmembrane segment, indicate the orientation of
α-helices H1–H6. The visible hydrophobic residues are highlighted in dark gray and
labeled. The homology structural model has been represented using the molecular
visualization program VMD.
Fig. 2. Diagram of the CAC structure depicting the location of the mutated residues
facing the central cavity. The transmembrane segments (H1–H6) of the CAC are repre-
sented by cylinders; segments H3, H4 and H5 are transparent. The residues are
highlighted by colors as indicated.
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On the basis of the bioinformatic predictions three sets of residues
have been substituted: (1) hydrophobic residues of H1, H2 and H6
protruding in the central cavity, which may be hypothetically
involved in acylcarnitine binding (Fig. 2); (2) hydrophobic residues
of H3, H4 and H5 facing the cavity, which are not expected to be
critical for acylcarnitine binding (Fig. 2); (3) some hydrophobic resi-
dues of H1, H2 and H6 that do not protrude towards the cavity that
have been mutated as negative controls. Residues have been
mutated with A or G and in some cases with M. The effect of the
mutations of each transmembrane segment, in terms of variations
of the GRAVY index, is reported in supplementary Table S1. In all
the cases variations below 15% of the index were observed, except
in the case of the most hydrophilic H4. The overall hydrophobicity
of the entire protein was not signiﬁcantly inﬂuenced (less than 7%)
by each of the mutations (not shown). The mutant proteins, over-
expressed in E. coli, have been reconstituted in liposomes for func-
tional characterization. The efﬁciency of incorporation of the protein
into the liposomal membrane has been tested as previously described
[14]. No signiﬁcant differences of incorporation were observed for the
various mutants (not shown) as previously found for several other
mutants of CAC [14,15,17]. The transport activity of each mutant
has been tested in proteoliposomes as time course of [3H]carnitine/
carnitine antiport, in comparison with the WT (Fig. 3). Most of the
mutants of hydrophobic residues protruding towards the central
cavity (Fig. 3A–D, white symbols), exhibited transport activities com-
parable to or above 70% of that of WT, such as L14A, V25A and V25M
(H1; Fig. 2 A), V82A, V82M, M85A and F93A (H2; Fig. 3 B), A276G,
C283A and F287A (H6; Fig. 3 C), A182G (H4; Fig. 2 D), V212A (H5;
Fig. 3 D). Some mutants showed lower activities, with transport at
30 min ranging from 20% to 50% of the WT activity, such as G21A
(H1; Fig. 3 A), P78A, P78M and C89A (H2; Fig. 3 B), A279G (H6;
Fig. 3 C); only G17A and G21M (H1; Fig. 3 A), M128A (H3; Fig. 3 D)
were inactive (transport activity lower than 5% of the WT). The mu-
tants of residues that do not protrude towards the cavity (Fig. 3,
black symbols), i.e., V22A and C23A of H1 (Fig. 2 A), M75A andF86A of H2 (Fig. 3 B), A281G of H6 (Fig. 3 C), showed transport func-
tion similar or above 70% of that of WT, with the exception of L24A
(H1), which exhibited transport activity at 30 min, of 40% respect to
the WT. Thus, with few exceptions, the mutations performed did
not cause strong impairment of transport function. On the contrary,
substitutions of the residues with polar ones led, in general, to strong
impairment of function (not shown).
3.3. Proﬁle of inhibition of CAC mutants by acylcarnitines
Acylcarnitines behave as competitive inhibitors towards carnitine
since they bind to the same site of the transporter (refs. [10,16] and
see Fig. 5 below). Thus, the effect of the mutations on the interaction
of CAC with acylcarnitines of various lengths can be tested by study-
ing their inhibition proﬁle. For this purpose the residual activity, i.e.,
the residual [3H]carnitine/carnitine antiport in the presence of acyl-
carnitines of various lengths respect to the control (in the absence
of inhibitor) has been measured. The residual activity of the mutants
has been compared with the residual activity of the WT, in the pres-
ence of each acylcarnitine (Fig. 4). For a reliable estimation of the
variations, the concentration of each inhibitor has been chosen (see
legend of Fig. 4) to obtain, in the WT, residual activities of roughly
50%. Due to methodological reasons, consistent ﬂuctuations (S.D.
values) affected the experimental data in these experiments. Thus, a
statistical analysis was performed to evaluate signiﬁcant differences
respect to the WT. Fig. 4A shows the effect of the substitutions with
A (and M in the case of V25) of residues of H1, which face into the
central cavity. While for the mutants L14A and G21A no signiﬁcant
variations were found, in the case of V25A a signiﬁcant increase of
residual activity, i.e., decrease of inhibition was observed with all
acylcarnitines with very little difference from C2 to C14. In the mutant
V25M, the decrease of inhibition became more evident with acylcar-
nitines from C4 to C8 and disappeared with longer carbon chains.
Fig. 4B and C shows the effect of the substitutions with A (and/or
Met) of residues of H2 that face into the central cavity. The substitu-
tion of P78 with A caused extensive decrease of inhibition, respect
to the WT, with all the acylcarnitines from 48% for C2 to more than
Fig. 3. Time course of [3H]carnitine uptake in liposomes reconstituted with recombi-
nant CAC proteins. Transport was started by the addition of 0.1 mM [3H]carnitine to
proteoliposomes containing 15 mM carnitine and stopped at the indicated times:
(A) mutants of H1, (B) mutants of H2, (C) mutants of H6, (D) mutants of other helices.
In each panel the data relative to the WT CAC are shown with those relative to the
mutants, as indicated in the legends. White symbols or black symbols refer to mutants
of residues, which protrude or do not protrude, respectively, towards the central cavity
of CAC structural model. The data represent means±SD of at least three independent
experiments.
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(Fig. 4 B). The substitution of P78 with Met, instead of A, caused sim-
ilar but less remarkable variations especially in the case of C16. The
mutation V82A caused signiﬁcant increase of residual activity, i.e.,
decrease of inhibition above 13%, only in the case of acylcarnitinesfrom C8 to C16. The substitution of V82 with M instead of A caused
a more evident decrease of inhibition with the same acylcarnitines.
In the case of M85A (Fig. 4 C), similar to the mutants of V82, no effect
was observed with C2 and C4, but strong effects (more than 50%
decrease inhibition) with acylcarnitines with longer chains. Again
similar variations, even though less pronounced, were observed for
the C89A mutant. The F93A mutant did not show signiﬁcant effects.
Fig. 4D shows the effect of the substitutions with A (or G in the
cases in which A was the native residue) of residues of H6, which
face towards the central cavity. The substitution A276G caused signif-
icant decrease of inhibition only with acylcarnitines from C12 to C16
ranging from 13% to 45%. The mutant A279G showed decrease of
inhibition by all acylcarnitines. Surprisingly, the mutation C283A
caused decrease of residual activity, i.e., an increase of inhibition,
respect to the WT, with acylcarnitines from C8 to C16. A smaller
and less signiﬁcant increase of inhibition was observed with shorter
(C2 and C4) acylcarnitines. Whereas the mutant F287A did not
show signiﬁcant variations.
The mutants of residues of H1, H2 and H6 which do not face the
central cavity, V22A, C23A, L24A, M75A, F86A and A281G (Fig. 4E
and F) as well as the mutants of the hydrophobic residues, facing
the central cavity, located on H4 (A182G) and H5 (V212A) (Fig. 4 F)
did not exhibit signiﬁcant variation of inhibition by acylcarnitines.
The only exception was observed for the effect of C2 on A182G: in
this case a signiﬁcant decrease of residual activity, i.e., increase of in-
hibition was observed. The charged residues that were previously
found to interact with free carnitine were also tested for variations
of inhibition by acylcarnitines. With the exception of H29 [15], no sig-
niﬁcant variations were found in all the other cases (not shown). It
has to be stressed, however, that for the residues D179, R275, K35
and E132 only conservative mutants could be analyzed since other
mutants were inactive [14].
3.4. Kinetics of the CAC mutants
The Vmax and Km for carnitine have been measured for the
mutants of residues that face the central cavity (Table 1). Vmax
could not be determined for G17A and G21M and was strongly
impaired in G21A, V25M and P78M, which showed values lower
than half respect to the WT. Concerning the Km values, only G21A,
P78A and P78M showed Kms more than two fold that of the WT.
Thus, the strongly impaired mutants resulted to be G21A, V25M and
P78M with catalytic efﬁciency (Vmax/Km) lower than 20% of WT.
All the other mutants showed smaller variations respect to the WT,
indicating that most of mutations did not inﬂuence signiﬁcantly the
binding and translocation of free carnitine.
The effect of the substitutions on the kinetic parameters of the
CAC for acylcarnitines of C2, C8 and C16 was evaluated for some of
the mutants, which showed signiﬁcant variations of the inhibition
proﬁle (see Fig. 4). To obtain half saturation constants for acylcarni-
tines, Ki values were derived from experiments in which the effect of
acylcarnitines was evaluated at various [3H]carnitine concentra-
tions. In Fig. 5 the patterns of inhibition of the WT (Fig. 5 A) and
the mutant M85A (Fig. 5 B), as an example, by acylcarnitines (C2,
C8 and C16) are reported. The acylcarnitines clearly behaved as com-
petitive inhibitors in agreement with previous data [10,16]; the same
inhibition pattern was observed for all the other mutants (not
shown). The Ki values of the WT and mutants derived from the inhi-
bition kinetic experiments are reported in Table 2. The lowest Ki
value of the recombinant WT CAC was found for C16. It increased
about three times for C8, and the Ki for C2 was more than one
order of magnitude higher than that for C16. These data indicated
that the transporter exhibits higher afﬁnity for longer acylcarnitines
in agreement with previous data obtained with the native CAC puri-
ﬁed from rat liver mitochondria [16]. The mutant V25A showed
higher Ki for acylcarnitines respect to the WT; the strongest
Fig. 4. Inhibition proﬁle of CACmutants by acylcarnitines. The carnitine acyl derivatives with the indicated (n) carbon chain length were added to the reconstituted proteoliposomes
together with 0.1 mM [3H]carnitine. The concentrations used for acylcarnitines were 0.2 mM acetylcarnitine (C2) and butyrylcarnitine (C4); 0.025 mM octanoylcarnitine (C8);
0.01 mM lauroylcarnitine (C12), myristoylcarnitine (C14) and palmitoylcarnitine (C16). After 15 min the transport was stopped as indicated in Materials and Methods. Percent
age of residual activity are reported in comparison with the WT. In each panel (A–F) the colors related to the different mutants are indicated. The data represent means±S.D. of
three independent experiments. Signiﬁcantly different from the WT as estimated by the Student's t test (*pb0.05, **pb0.01).
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P78A showed the largest increment of Ki for C2 and C8 respect to the
WT, whereas the Ki could not be measured for C16, in agreement
with the almost complete loss of inhibition (Fig. 3 B). V82A and
C89A showed strong Ki increase for C16 and smaller increases for
C2 and C8; M85A showed strong increase of Ki for C8 and C16, in re-
spect to the WT. In the case of H6 strong Ki increments for the three
acylcarnitines were observed in the mutant A279G, whereas, in the
mutant A276G only the Ki for C16 increased; C283A showed reduc-
tions of Ki for C8 and C16, in respect to the WT. The variations of Ki
values mostly correlated with the variations of inhibition respect to
the WT, shown in Fig. 4. To predict the structural model of the inter-
actions among the critical residues and palmitoylcarnitine, a docking
analysis was performed using ArgusLab [25]. The model obtained is
shown in Fig. 6. The hydrophobic interactions among methylene
groups of the acyl chain and residues V25, P78, V82, M85, C89 of
H1 and H2 are depicted.4. Discussion
The structure of the CAC in the cytosolic state (c-state) was
previously constructed [11] by homology modeling using as template
the structure of the ANC in the c-state obtained by X-ray crystallogra-
phy [22]. In the c-state conformation, the protein is constituted by a
bundle of six transmembrane α-helices, which delimit a central
cavity closed towards the matrix by a network of three salt bridges.
The relationships between the transporter and the substrate carnitine
have been recently deﬁned by site-directed mutagenesis coupled
with bioinformatics. It has been found that R275, D179, K35, E132
and H29 are critical for the binding and translocation of free carnitine
[14,15]. Physiologically CAC catalyses the transport of acylcarnitines
with acyl groups of various lengths in exchange with carnitine. The
transporter exhibits higher afﬁnity (lower Ki) for longer acylcarni-
tines [10,16] (see also Table 2). On the basis of kinetic studies, it
was demonstrated that the binding site for these molecules overlaps
Table 1
Kinetic constants of reconstituted CAC mutants in comparison with the WT. The Km
and Vmax values were calculated from experiments in which the rates of carnitine/
carnitine antiport were measured at different external substrate concentrations. Cata-
lytic efﬁciencies are also reported (right column) as ratios Vmax/Km. Transport was
started by the addition of 0.12–2.0 mM [3H]carnitine to proteoliposomes reconstituted
with the WT CAC or one of the indicated mutants and containing 15 mM carnitine. The
transport time was 4 min. The data represent the means±S.D. of four different exper-
iments; nd, not detectable.
Protein Km (mM) Vmax (nmol/min/mg) Vmax/Km (ml/min/mg)
WT 0.48±0.091 1.8±0.54 3.8
L14A 0.60±0.12 1.0±0.31 1.7
G17A nd nd nd
G21A 0.96±0.17 0.45±0.080 0.47
G21M nd nd nd
V25A 0.87±0.077 1.7±0.15 1.9
V25M 0.90±0.059 0.62±0.17 0.69
P78A 1.1±0.10 1.6±0.55 1.5
P78M 1.2±0.15 0.72±0.26 0.60
V82A 0.60±0.15 1.5±0.81 2.5
V82M 0.38±0.083 2.0±0.80 5.3
M85A 0.57±0.15 2.1±0.090 3.7
C89A 0.88±0.11 1.0±0.092 1.1
F93A 0.56±0.082 1.1±0.31 2.0
A276G 0.80±0.10 1.7±0.73 2.1
A279G 0.80±0.22 0.93±0.42 1.2
C283A 0.49±0.070 1.4±0.18 2.8
F287A 0.43±0.11 1.2±0.75 2.8
Fig. 5. Kinetic analysis of the inhibition of the recombinant transporters by acylcarniti-
nes.The carnitine/carnitine antiport rate was measured, as described in Materials and
Methods, adding [3H]carnitine at different concentrations to proteoliposomes contain-
ing 15 mM carnitine, in the absence or in the presence of acylcarnitines. Experimental
data for WT (A) and M85A (B) plotted according to Lineweaver–Burk as reciprocal
transport rate vs. reciprocal carnitine concentrations in the absence (○) or in the
presence of 250 μM acetylcarnitine (C2, ●), 25 μM octanoylcarnitine (C8, □) or 10 μM
palmitoylcarnitine (C16, ■). The data represent means±SD from at least three inde-
pendent experiments.
Table 2
Ki values for acylcarnitines of CAC mutants. The Ki values were calculated from double-
reciprocal plots obtained from rates of carnitine/carnitine antiport under variation of
the external substrate concentration in the absence or presence of 250 μM acetylcarni-
tine (C2), 25 μM octanoylcarnitine (C8) or 10 μM palmitoylcarnitine (C16). Transport
was started by the addition of 0.12–2.0 mM [3H]carnitine to proteoliposomes reconsti-
tuted with the WT CAC or one of the indicated mutants and containing 15 mM carni-
tine. The transport time was 4 min. The data represent the means±S.D. from three
different experiments; n.d., not detectable.
Protein Ki C2 (μM) Ki C8 (μM) Ki C16 (μM)
WT 120±13 15±1.9 5.4±0.53
V25A 430±34 43±5.2 8.1±0.90
P78A 640±32 60±3.2 nd
V82A 155±9.6 26±1.8 20±2.8
M85A 190±19 44±1.9 26±3.8
C89A 180±47 23±1.8 20±1.0
A276G 124±21 20±4.1 28±2.0
A279G 520±94 35±2.2 nd
C283A 110±12 8.0±1.2 3.0±0.28
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binding site also contains hydrophobic amino acid side chains. To
identify these residues, we have studied the alterations of the inhibi-
tion proﬁle of acylcarnitines of various lengths caused by mutations of
hydrophobic residues protruding into the central cavity of the trans-
porter. The residues have been substituted with smaller hydrophobic
residues: A or G, if the WT amino acid was A. These substitutions
cause mainly changes in the volume of the residues, without signiﬁ-
cantly affecting the overall hydrophobicity of each α-helix (Table
S1). Consequently, each of the substitutions would have the desired
effect to abolish or reduce interactions among the amino acid side
chains and the hydrophobic moiety of the acylcarnitines, causing var-
iations of the inhibition. Eight of the mutated hydrophobic residues
protruding into the cavity on the half shell made by H1, H2 and H6,
inﬂuence the proﬁle of sensitivity of the transporter towards acylcar-
nitines. Four of these residues are located on H2 indicating that it is
the most critical transmembrane α-helix for acyl group recognition.
A similar important role of the second transmembrane segment in
the binding of acetylcarnitine was hypothesized on computational
basis for the yeast mitochondrial carnitine transporter. In that case
the residues predicted to be critical for acetyl group binding were
I89 and F90 [26], which are homologues of M85 and F86 of the rat
CAC. More recently, the importance of the second transmembrane
segment had also been predicted for the mitochondrial CIC [27],
which, however, recognizes anionic substrates. The mutations of crit-
ical residues in most cases had no or slight effect on the transport ac-
tivity and Km for free carnitine, whereas affected the half saturation
constants (Ki) for speciﬁc acylcarnitines (Table 2), indicating that
the variations are mainly due to effect of mutations on the binding
of the acyl chains to the transporter. Both variations of proﬁle of inhi-
bition and of Ki indicated that substitution of V25 and P78, which are
located deeply in the central cavity (bottom residues), affected the in-
teraction of the protein with all the acylcarnitines, i.e., acylcarnitines
from C2 to C16 interact with the bottom residues. Whereas, substitu-
tion of V82, M85 and C89, which are located at about the midpoint of
the membrane (middle residues), affected the interaction of longer
acylcarnitines, i.e., only acylcarnitines from C8 to C16 interact with
the middle residues. Some of the critical residues have also been
substituted with Met, which is larger and, differently from A,increases the sterical hindrance. The effects observed in these mu-
tants conﬁrmed the conclusions drawn from the A mutants. Indeed
the effect of mutation was similar respect to the A mutants. Only in
the case of the bottom residues (P78M and V25M) longer acyl chains
were less affected by the mutations. This last observation may be
explained by the capacity of longer chains to assume different stable
conformations, which adapt better than short chains to the increased
sterical hindrance in the deeper part of the binding pocket. However,
the effect observed in the P mutants, which is more evident than
those of other residues could also be explained by a generalized alter-
ation of structure and mobility of the protein. Indeed, it is well known
that P residues affect the structure of α-helices.
Fig. 6. Interaction of the CAC with palmitoylcarnitine. (A) Lateral view of the CAC structural model with bound palmitoylcarnitine. The transmembrane α-helices H1 (on the right)
and H2 (on the left) are opaque whereas H3, H4, H5 and H6 are transparent. CAC residues involved in the interaction and the palmitoylcarnitine molecule are depicted in a ball and
stick or tube representation, respectively. (B) Enlarged view of the residues interacting with palmitoylcarnitine.
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tal results on H1 and H2 (Fig. 6), depicts palmitoylcarnitine as an
example of acylcarnitines, oriented from the bottom to the edge of
the cavity. This correlates well with the previous data describing the
interaction of the carnitine moiety with residues K35, E132 and
H29, which are located just below the hydrophobic bottom residues
[14,15] and with the ﬁnding that substitution of residues that are
located at a more superﬁcial position (L14 and F93) did not affect
the inhibition, i.e., the binding of acylcarnitines (see Fig. 4). It should
be further considered that the central cavity of the transporter con-
tains water molecules. Thus, also the more hydrophobic substrates
such as longer acylcarnitines (C12–C16) would interact with some
water molecules. Since acylcarnitines have been used at concentra-
tions lower than their CMC [28], the molecules are in a monomer
state in water. The solubility in this condition should be facilitated
by formation of convoluted acyl chain structures that minimize the
contact surface with water before the acyl chain binds to the hydro-
phobic binding site. The binding of the hydrophobic moiety does
not constitute per-se the basis for substrate selectivity, which, indeed,
is determined by the overall interactions, including binding of polar
groups of carnitine to charged residues, as previously described
[14]. The hydrophobic interaction protein-acyl group provides the
molecular basis for increased afﬁnity respect to free carnitine. Indeed,
the number of interactions of amino acid residues with acyl chains in-
creases with the chain length, explaining the higher afﬁnity of CAC
(lower Ki) for longer acylcarnitines [16] (see Table 2). G21 and G17
are not critical for the interaction with acyl groups. However, the
lack of activity of the mutants G17A and G21M indicates that the
two residues may play a role in the conformational changes involved
in the translocation process, as previously predicted for the mito-
chondrial carrier family [29]. Apparently, the experimental data on
H6 did not ﬁt with those on H1 and H2. In particular, the substitution
of C283 led to increase, not decrease, of inhibition by longer acylcar-
nitines. A plausible explanation for these ﬁndings may be that H6 in-
teracts with the acylcarnitines when the carrier is in a conformation
different from the c-state. Even though there are no experimental
evidences yet, the existence of alternative conformations is in line
with previous ﬁndings indicating that the binding of free carnitine
to the CAC induces changes of conformation of the protein [13,14]
and with the prediction that mitochondrial carriers undergo from c-
state to m-state opened towards the matrix through a transition
state [26,29–31]. The residues of H6 may have a role in this transitionstate. On the basis of the experimental data (Fig. 4 and Table 2), C283,
getting closer to H2, may favor the displacement of the acyl moiety of
acylcarnitines from H2 and release in the matrix. The anomalous in-
crease of inhibition (binding) by longer acylcarnitines caused by mu-
tation of C283 (Fig. 4 and Table 2) is thus explained by a decreased
efﬁciency in displacing the acyl group from H2. The results of muta-
tions of A276 and A279 with G may also be explained by a more gen-
eralized effect on the α-helix structure. This hypothesis correlates
well with the previous ﬁnding that residues of H6 are involved in
inter-helical interaction [11] and with the prediction of a cytosolic
network of six residues, which are distant in the c-state and get
close to each other when the protein is in the m-state [14,26]. Two
of these six residues G94 and M291 are located on the H2 and H6,
just above C89 and C283, respectively. Thus also C89 and C283
could get closer in the m-state. Interestingly, all the residues involved
in the interaction with the acyl moiety are fully conserved only in the
mammalian and zebra ﬁsh CAC proteins (not shown). This ﬁnding
correlates well with the role of CAC in these organisms to provide
mitochondria with medium-long acylcarnitines for β-oxidation. To
our knowledge, this work represents the ﬁrst description at molecu-
lar level of interaction between hydrophobic molecules and a mem-
ber of the mitochondrial carrier family.
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